HFA 2025

Richmond Pharmacology is pleased to announce our participation in Heart Failure 2025, the annual congress of the Heart Failure Association of the ESC, taking place this year in Serbia. The event is a key platform for advancing science, clinical practice, and collaboration in heart failure and related cardiovascular conditions.

Bringing together global experts, this year’s congress will spotlight breakthroughs in cardiology, digital health, and innovative approaches to heart failure management.

Representing Richmond Pharmacology:

• Dr Jörg Täubel, Chief Executive Officer
• Aga Krakowiak, Lead Research Physician

James Rickard, Chief Scientific Officer, Richmond Research Institute (include link to RRI website), will be presenting two posters from collaborative research with Richmond during this event. 

1. The use of Symmetric Projection Attractor Reconstruction (SPAR) to detect ECG changes corresponding to cardiac deterioration in transthyretin amyloid cardiomyopathy (ATTR-CM).
2. Disparities in Clinical Trial Access for Black Patients with ATTR-CM. Investigating racial disparities in access to clinical trials for ATTR-CM, particularly among Black African and Black Caribbean patients.

If you are attending HFA 2025 and seeking a proven clinical partner in cardiovascular research, we invite you to connect with us during the event.

For meeting requests or collaboration enquiries:
info@richmondpharmacology.com

Learn more about the event: